PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis-Reference-Cited by-同舟云学术

PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis

Published:2023-05 Issue:6 Volume:164 Page:966-977.e17
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Chen Vincent L.^ORCID,Oliveri Antonino,Miller Matthew J.,Wijarnpreecha Karn,Du Xiaomeng,Chen Yanhua,Cushing Kelly C.,Lok Anna S.,Speliotes Elizabeth K.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference53 articles.

1. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018

2. Attributable fractions of nonalcoholic fatty liver disease for mortality in the United States: results from Third National Health and Nutrition Examination Survey with 27 years of follow-up;Alvarez;Hepatology,2020

3. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe;Younossi;Hepatology,2016

4. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease;Canbay;Aliment Pharmacol Ther,2020

5. Progression and natural history of nonalcoholic fatty liver disease in adults;Marengo;Clin Liver Dis,2016

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort;Journal of Hepatology;2024-09

2. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

3. Metabolic dysfunction−associated liver disease and diabetes: Matrix remodeling, fibrosis, and therapeutic implications;Annals of the New York Academy of Sciences;2024-07-12

4. Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction–associated steatotic liver disease;Hepatology Communications;2024-07

5. Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants;JHEP Reports;2024-07